Last reviewed · How we verify
Coly-Mycin S (COLISTIN)
At a glance
| Generic name | COLISTIN |
|---|---|
| Sponsor | Par Sterile Products |
| Drug class | colistin |
| Target | Melanocortin receptor 3 |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1962 |
Approved indications
- Enterobacter Infection
- Infection due to Escherichia coli
- Klebsiella Infections
- Mastoidectomy Cavity Infections
- Otitis externa
- Pseudomonas Aeruginosa Infections
Common side effects
- Skin atrophy
- Secondary infection
- Maceration of the skin
- Miliaria
- Hypertrichosis
- Hypopigmentation
- Folliculitis
- Dryness
- Irritation
- Itching
- Burning
- Acneiform eruptions
Key clinical trials
- Phenotypic and Genotypic Detection of Colistin Resistance
- A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
- A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
- Effect of Diluent Volume on Colistin Inhalation Therapy (NA)
- Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia (PHASE2,PHASE3)
- Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity (PHASE2,PHASE3)
- Therapeutic Options for CRAB (PHASE4)
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |